Volume : 10, Issue : 02, February – 2023
Title:
18.FORMULATION AND EVALUATION OF FLOATING TABLET OF RISEDRONATE
Authors :
K.Nagamani, D.Rajkumar
Abstract :
Single and multi-unit skimming systems of risedronate sodium were readied utilizing Gelucire 43/01 by lessen cementing and separate granulation framework, solely. The controlled delivery drifting systems were assessed for in vitro and in vivo skimming limit and in vitro quiet delivery. Impact of creating on Gelucire 43/01 was overviewed by hot stage microscopy (HSM), isolating electron microscopy (SEM), differential taking a gander at calorimetry (DSC), in vitro skimming limit, and in vitro fix discharge. Multi-unit framework got has shown starting affected delivery, which was covered in single unit structure. Both single-and besides multi-unit structures displayed expansion in pace of medication discharge on creating because of changes in the properties of the Gelucire 43/01. Multi-unit structures picked up by separate granulation were adequately less mentioning for scale up and valuable if the essential burst discharge doesn’t make any indispensable clinical misery.
Keywords: Formulation, Evaluation, Floating Tablet, Risedronate
Cite This Article:
Please cite this article in press K.Nagamani et al, Formulation And Evaluation Of Floating Tablet Of Risedronate., Indo Am. J. P. Sci, 2023; 10 (02).
Number of Downloads : 10
References:
2. [2] C. Sauzet, M. Claeys-Bruno, M. Nicolas, J. Kister, P. Piccerelle, P. Prinderre, An innovative floating gastro retentive dosage system: formulation and in vitro evaluation, Int. J. Pharm. 378 (1–2) (2009) 23–29.
3. [3] R. Garg, G.D. Gupta, Progress in controlled gastroretentive delivery systems, Trop. J. Pharm. Res. 7 (3) (2008) 1055–1066.
4. [4] X. Xiaoqiang, S. Minjie, Z. Feng, H. Yiqiao, Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers, Int. J. Pharm. 310 (2006) 139–145.
5. [5] A.A. Deshpande, N.H. Shah, C.T. Rhodes, W. Malick, Development of a novel controlled release system for gastric retention, Pharm. Res. 14 (1997) 815–819.
6. [6] M.D. Chavanpatil, P. Jain, S. Chaudhari, R. Shear, R.R. Vavia, Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin, Int. J. Pharm. 316 (1–2) (2006) 86–92.
7. [7] S.J. Hwang, H. Park, K. Park, Gastric retentive drugdelivery systems, Crit. Rev. Ther. Drug Carrier Syst. 15 (3) (1998) 243–284
8. [8] P.R. Seth, J. Tossounian, the hydrodynamically balanced system, a novel drug delivery system for oral use, Drug Dev. Ind. Pharm. 10 (1984) 313–339.
9. [9] R.M. Harrigan, Drug Delivery Device for Preventing Contact of Undissolved Drug with the Stomach Lining, US Patent 4055178, October 25, 1977.
10. [10] L. Whitehead, J.T. Fell, J.H. Collett, Development of a gastroretentive dosage form, Eur. J. Pharm. Sci. 4 (Suppl.) (1996) S182.
11. [11] Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, Y. Itoh, Hollow microspheres for use as a floating controlled drug delivery system in the stomach, J. Pharm. Sci.81 (1992) 135–140.
12. [12] J. Chen, W.E. Blevins, H. Park, K. Park, Gastric retention properties of superporous hydrogel composites, J. Control. Release 64 (1-3) (2000) 39–51.
13. [13] R. Gröning, M. Berntgen, M. Georgarakis, Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracoporal magnets to control gastrointestinal transit, Eur. J. Pharm. Biopharm. 46 (1998) 285–291.
14. [14] H. M. Ingani, J. Timmermans, A. J. Moes. Conception and in vivo investigation of peroral sustained release fl oating dosage forms with enhanced gastrointestinal transit. Int. J. Pharm., 1987, 35: 157-164.
15. 15] A. A. Deshpande, N. H. Shah, C. T. Rhodes, et al. Development of a novel controlled-release system for gastric retention. Pharm. Res., 1997, 14: 815-819.
16. [16] Physicians’ Desk Reference (PDR), 65th ed. PDR Network, Montvale, 2011; p. 3352-60.